Today, the 28th China Beijing International High-Tech Expo (“CHITEC”) officially opened in Beijing, comprehensively showcasing China’s cutting-edge technological and innovative achievements across frontier technologies, emerging industries, future industries, and other related fields. As an outstanding innovative enterprise in the field of neurointervention, AccuMedical Beijing Inc.(hereinafter referred to as “AccuMedical”) was invited to participate in the exhibition, systematically presenting its “full-stack neurointerventional solutions” centered on the diagnosis and treatment of hemorrhagic and ischemic stroke, as well as cerebrovascular access systems.
During the exhibition, AccuMedical’s two latest independently developed treatment solutions attracted significant attention. For the treatment of acute ischemic stroke (AIS, also known as cerebral infarction), AccuMedical introduced an integrated vascular recanalization solution centered on the Grism® Stent Retriever, featuring coordinated compatibility with multiple devices to provide clinicians with a safer and more efficient recanalization option. Addressing the current clinical challenge that chronic/subacute subdural hematoma can only be treated through surgical intervention and lacks minimally invasive treatment options, AccuMedical’s innovative product, the Coincide® Liquid Embolic System , is expected to fill this procedural gap.
(AccuMedical booth at the Beijing International High-Tech Expo)
Full-Stack Synergy: Grism® Integrated Recanalization Solution Addresses the Challenge of Clot Fragment Escape During Thrombectomy
(AccuMedical Integrated Recanalization Solution for Acute Ischemic Stroke)
Acute ischemic stroke is highly prevalent in China, while the therapeutic window for intervention remains limited Conventional thrombectomy procedures continue to face major clinical challenges, including thrombus fragmentation leading to distal embolic escape and re-embolization, as well as difficulties in navigating tortuous vasculature that prolong procedural time, all of which present significant challenges for neurointerventional physicians. AccuMedical’s integrated recanalization solution for acute ischemic stroke, centered on the Grism® Stent Retriever, achieves coordinated compatibility among multiple original devices, enabling a “one-stop” procedural design spanning vascular access establishment, thrombus retrieval, and distal embolic protection. The solution provides seamless procedural integration and smooth device operability, significantly improving vascular recanalization efficiency [1].
As the core component of the solution, the Grism® Stent Retriever features the world’s first fully radiopaque dual capture tripods and a distal closed no-tip design [2], enabling effective thrombus capture while preventing clot fragment escape. Particularly noteworthy is that the product’s pre-market clinical study, Grism Recanalization Device for Endovascular Treatment of Acute Ischemic Stroke within 24 hours (GREAT-24), breakthroughly expanded the enrollment treatment window from the conventional 8 hours to 24 hours. Moreover, 37% of enrolled patients were late-window patients treated within 8–24 hours after stroke onset. This forward-looking exploration of expanded treatment windows is expected to provide acute ischemic stroke patients with improved treatment opportunities.In recognition of its outstanding innovation, the Grism® Stent Retriever has been included in the Zhongguancun Innovative Medical Device Product Catalog.
To further ensure smooth procedural performance, the solution also integrates the Attractor® Intracranial Aspiration Catheter, featuring excellent aspiration capability; the Cosine® 45 Distal Access Catheter, capable of establishing stable intracranial support access; and the Sine® 21 Microcatheter, which demonstrates excellent trackability and compliance within delicate and tortuous cerebral vasculature. The full-stack product portfolio demonstrates outstanding system synergy in complex tortuous vessels, providing more valuable opportunities for patient rescue and neurological function recovery.
Forward-Looking Pipeline Strategy: Original Innovation in Liquid Embolic Systems Expected to Fill Domestic Interventional Treatment Gap
(AccuMedical investigational product: Coincide® Liquid Embolic System)
At this year’s Beijing International High-Tech Expo, AccuMedical also showcased its key investigational product, the Coincide® Liquid Embolic System. The product is primarily intended for the treatment of chronic/subacute subdural hematoma and is currently in the clinical trial stage. At present, the disease is primarily treated through surgical procedures in China, with no dedicated interventional treatment solution available. Following commercialization, Coincide® is expected to fill this domestic gap by providing patients with a more minimally invasive and precise treatment option.The research and development project was included in the Beijing Municipal Science and Technology Program for the Cultivation of Innovative Pharmaceutical Products and Platforms in 2025.
From the innovation leadership of the Lattice® Flow Diverter series, to the frontier exploration represented by the Grism® Stent Retriever, and further to original breakthroughs in liquid embolic agents, AccuMedical is accelerating its transformation into a comprehensive industry leader across the full neurointerventional landscape.Leveraging its efficient R&D translation capabilities and global operational system, the company has established a tiered growth-driving structure characterized by “commercialized products consolidating scale, core second-tier pipelines driving growth momentum, and reserve pipelines strategically positioning future opportunities.” While providing momentum for the high-quality growth of China’s innovative medical device industry, AccuMedical is also contributing “China Solutions” to global cerebrovascular health.
Notes
[1] Results from the pre-market clinical study Grism Recanalization Device for EndovAscular Treatment of Acute Ischemic Stroke within 24 hours (GREAT-24) demonstrated that the first-pass recanalization rate of the Grism treatment group reached 58.6%, compared with 48.5% in the control group.
[2] As of August 22, 2025.